Shanghai perhum therapeutics
WebbShanghai PerHum Therapeutics ("PerHum") was formed in 2016 for the express purpose of developing novel CAB-CAR-T therapies for solid tumor malignancies in China. Contact … Webb6 maj 2024 · Shanghai PerHum Therapeutics Co., Ltd. ClinicalTrials.gov Identifier: NCT05128786 Other Study ID Numbers: CCT301-38-SAR First Posted: Nov 22, 2024 Last …
Shanghai perhum therapeutics
Did you know?
Webb22 feb. 2024 · Contact Information Website www.perhum.com Formerly Known As Shanghai Weiming Xuhang Biotechnology Co., Ltd., Shanghai Xuhang Biotechnology Co., … Webb23 maj 2024 · - German biotechnology company Exuma biotechnology and affiliate Shanghai PerHum Therapeutics have presented interim results of two first-in-human …
Webb21 maj 2024 · Frannie Marmorstein. +1 305-567-0821. [email protected]. TimeLine: Announces Preliminary Results of Two, EXUMA Biotechnology's Affiliate Shanghai PerHum. Webb21 maj 2024 · EXUMA Biotechnology’s Affiliate Shanghai PerHum Therapeutics Announces Preliminary Results of Two First-in-Human Solid Tumor CAR-T Products Data …
WebbA Phase I Trial of CCT303-406 in Patients With Relapsed or Refractory HER2 Positive Solid Tumors (clinicaltrials.gov) - P1 N=15 Recruiting Sponsor: Shanghai PerHum Therapeutics Co., Ltd. Trial completion date: Apr 2024 --> Oct 2024 Trial primary completion date: Apr 2024 --> Oct 2024. Webb10 nov. 2024 · May 5, 2024 updated by: Shanghai PerHum Therapeutics Co., Ltd. A Phase I Trial to Assess Safety, Tolerability and Anti-tumor Activity of Autologous T Cell Modified Chimeric Antigen Receptor (CAR) (CCT301-38) in Patients With Relapsed or Refractory AXL Positive Sarcomas.
Webb21 maj 2024 · EXUMA Biotechnology and affiliate Shanghai PerHum Therapeutics announced today interim results of two first-in-human solid tumor CAR-T products in subjects with recurrent or refractory stage IV metastatic renal cell carcinoma (mRCC).
Webb21 maj 2024 · EXUMA Biotechnology and affiliate Shanghai PerHum Therapeutics announced today interim results of two first-in-human solid tumor CAR-T products in … gradle bad address connectWebb22 maj 2024 · MAINZ, Germany -- (BUSINESS WIRE) --. EXUMA Biotechnology and affiliate Shanghai PerHum Therapeutics announced today interim results of two first-in-human … gradle behind proxyWebbShanghai PerHum Therapeutics Co., Ltd, a company incorporated in Shanghai in 2016, focuses on developing innovative cancer treatments in the field of adoptive cellular … gradle bootstrapclasspathWebb21 maj 2024 · MAINZ, Germany--(BUSINESS WIRE)-- EXUMA Biotechnology and affiliate Shanghai PerHum Therapeutics announced today interim results of two first-in-human … chimege translateWebb12 sep. 2024 · There are two main strategies to develop drugs targeting Axl-GAS6. One is to directly inhibit Axl, and the other is to inhibit GAS6 to prevent its binding to Axl, i.e., ligand capture. These drugs are suitable for tumor drug resistance therapy or … chime get tax return earlyWebbPerhum therapeutics has developed a modified chimeric antigen receptor ... Shanghai Pu'er Biotechnology Overview. Founded Year 2016. Location Shanghai, China. Company Stage Funding Raised. Similar Cos. Ginkgo Bioworks, Human Longevity, Amyris, Bionano Genomics, Relay Therapeutics & 3271 others. gradle aws s3Webb10 aug. 2024 · Shanghai PerHum Therapeutics Co., Ltd. Collaborator Shanghai Zhongshan Hospital Provider of Information About this Clinical Study Sponsor Conditions in This Trial Solid Tumor Gastric Cancer Breast Cancer Ovarian Cancer Sarcoma Additional Key Areas Provided by Investigators HER2 CAR-T Solid tumors Interventions in This Trial CCT303-406 gradle bootrun hot reload